Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Daniela Wehler"'
Autor:
K Langeveld, Matthias Theobald, Eva Distler, Daniela Wehler, Simone Thomas, D Marandiuc, Daniel Teschner, Wolfgang Herr, Michaela Frey
Publikováno v:
Bone Marrow Transplantation. 49:138-144
Depletion of naive T cells from donor leukapheresis products (LPs) aims at the reduction of alloreactivity, while preserving memory T-cell reactivity (for example, to pathogens). This study established the immunomagnetic depletion procedure under cle
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f1c98041a5433fbf5f320ba9977f3f69
https://doi.org/10.1038/bmt.2013.114
https://doi.org/10.1038/bmt.2013.114
Autor:
Eva Distler, Charis von Auer, Karin Kolbe, Daniela Wehler, Christoph Huber, Elke Schnürer, Eva Wagner, Ralf G. Meyer, Wolfgang Herr, Bodo Plachter
Publikováno v:
Biology of Blood and Marrow Transplantation. 14:1417-1424
Reactivated varicella-zoster virus (VZV) infection causes herpes zoster and commonly occurs after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Because VZV-specific T cell immunity is essential to prevent virus reactivation, we deve
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0a3be9921fb217b3bbb2ae263d8eb390
https://doi.org/10.1016/j.bbmt.2008.09.004
https://doi.org/10.1016/j.bbmt.2008.09.004
Autor:
Abdo Konur, Thomas Wehler, Klaus Bender, Daniela Wehler, Georg Hess, Udo F. Hartwig, Cedrik M. Britten, Chiara Gentilini, Ralf G. Meyer, Christoph Huber, Lutz Uharek, Wolfgang Herr, Karin Kolbe, Andrew J. Ullmann
Publikováno v:
Blood. 109:374-382
Allogeneic hematopoietic stem cell transplantation (SCT) regimens incorporating the lymphocytotoxic CD52 antibody alemtuzumab demonstrate efficient engraftment and reduced graft-versus-host disease (GVHD). However, these protocols substantially impai
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3b760791d74f5dcd4e8eaa5a4687ca8c
https://doi.org/10.1182/blood-2006-03-005769
https://doi.org/10.1182/blood-2006-03-005769
Autor:
Daniela Wehler, Michael G. Kiehl, R Hartwig, Bernd Hertenstein, Kai Hübel, M. von Lilienfeld-Toal, Nadezda Basara, N Kröger, C Weigelt, Rita Beier, M.M. Fresen, Sebastian Theurich, Axel R. Zander, C Bogner, E Weidmann, Martin Ebinger, S Dressler, Norbert Frickhofen, H. Salwender, F Lordick, O Galm, Michael H. Albert, Maximilian Christopeit, F Lange, S Liebler, Wolf Rösler, F Heits
Publikováno v:
Bone marrow transplantation. 46(8)
The CXCR4-inhibitor plerixafor mobilizes hematopoietic stem cells amplifying the effects of granulocyte-CSF (G-CSF). Before approval plerixafor was used in a compassionate use program (CUP) for patients who failed a previous mobilization. In the Germ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::be58cd8288a777c0d6b35561e3cb4b93
https://pubmed.ncbi.nlm.nih.gov/20972470
https://pubmed.ncbi.nlm.nih.gov/20972470
Autor:
Eva Wagner, Eddy Roosnek, Timo Schmitt, Klaus Bender, Ralf G. Meyer, Christoph Huber, Abdo Konur, Udo F. Hartwig, Karin Kolbe, Daniela Wehler, Julia Hemmerling, Wolfgang Herr
Publikováno v:
Bone Marrow Transplantation, Vol. 45, No 4 (2010) pp. 668-674
Donor lymphocyte infusions (DLI) are used to resolve mixed T-cell chimerism (TCC) after allo-SCT despite a substantial risk of GVHD. We analyzed the impact of prophylactic CD8-depleted (CD8(depl)) DLI in 20 recipients of anti-CD52 alemtuzumab in vivo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f5d5b9b595c4b26ea54329058e72dffd
https://pubmed.ncbi.nlm.nih.gov/19684624
https://pubmed.ncbi.nlm.nih.gov/19684624
Autor:
Eva Wagner, Daniela Wehler, Wolfgang Herr, Aline N Lay, Timo Schmitt, Matthias Theobald, Karin Kolbe, Ralf G. Meyer
Publikováno v:
Blood. 122:4526-4526
We applied prophylactic CD8-depleted (CD8depl) donor lymphocyte infusions (DLI) in the setting of T-cell depleted reduced-intensity allogeneic hematopoietic stem cell transplantation (HSCT) in a phase I/II trial. T-cell depletion was carried out by t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bfb49e34c308a2840cf4cf5f322392b6
https://doi.org/10.1182/blood.v122.21.4526.4526
https://doi.org/10.1182/blood.v122.21.4526.4526
Autor:
Daniela Wehler, Matthias Theobald, Eva-Maria Wagner, Wolfgang Herr, Ralf G. Meyer, Karin Kolbe
Publikováno v:
Biology of Blood and Marrow Transplantation. 18:S215
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a7d5735658448757ef6cea1b30706a30
https://doi.org/10.1016/j.bbmt.2011.12.036
https://doi.org/10.1016/j.bbmt.2011.12.036
Autor:
Chiara Gentilini, Cedrik M. Britten, Christoph Huber, Abdo Konur, Karin Kolbe, Wolfgang Herr, Ralf G. Meyer, Udo F. Hartwig, Klaus Bender, Thomas Wehler, Lutz Uharek, Daniela Wehler
Publikováno v:
Blood. 106:297-297
The combination of fludarabin (150mg/m2) / melphalan (140mg/m2) based reduced-intensity allo-transplantation (RIT) with in vivo T-cell depletion (TCD) by the anti-CD52 antibody alemtuzumab (100mg) has demonstrated efficient engraftment and reduced gr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::16d5253c2cce1bdada9fafdbea92f1ea
https://doi.org/10.1182/blood.v106.11.297.297
https://doi.org/10.1182/blood.v106.11.297.297
Autor:
Cedrik M. Britten, Thomas Wehler, Alexander Burchardt, Ralf G. Meyer, Wolfgang Herr, Karin Kolbe, Daniela Wehler, Udo F. Hartwig, Christoph Huber
Publikováno v:
Blood. 104:5069-5069
Recent reports have demonstrated the feasibility of using the anti-CD52 antibody Campath-1H for in vivo T-cell depletion (TCD) in the context of a fludarabine/melphalan-based reduced-intensity conditioning regimen (Kottaridis et al. Blood 2000, 96:24
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6bd98f16f5bf41f70328e7d2add973b8
https://doi.org/10.1182/blood.v104.11.5069.5069
https://doi.org/10.1182/blood.v104.11.5069.5069